Skip to main content

Homing in on Demodex Blepharitis: Current and Emerging Treatment Strategies

Release Date: August 3, 2023
Expiration Date: August 3, 2024

Note: If you have already attended the 2023 Summit Series Live Event, you will not be able to log enduring credits

Activity Overview

This session, which was included as part of the 2023 Ophthalmology 360 Summit Series, will review the incidence/prevalence of Demodex blepharitis and strategies for making a timely diagnosis. It will also review current and emerging treatments and their safety and efficacy in treating this condition.

Target Audience

This activity is designed for an audience of ophthalmologists, optometrists, and other members of the healthcare team who treat patients with various eye conditions.

Learning Objectives

Upon completion of the educational activity, participants should be able to:
  • Describe the best approaches to the diagnosis and treatment of Demodex blepharitis
  • Discuss the latest clinical research in Demodex blepharitis
  • Implement the latest methods and data into clinical practice for the improved care of patients with Demodex blepharitis

Criteria for Success

To obtain a certificate of completion, a score of 70% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your certificate. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this activity, please contact AKH Inc. at

CE credit provided by AKH Inc., Advancing Knowledge in Healthcare

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and International Healthcare Media, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


AKH Inc., Advancing Knowledge in Healthcare designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

COPE - Optometrists

AKH Inc., Advancing Knowledge in Healthcare designates this asynchronous activity for a maximum of 1.0 COPE credit hours. Optometrists should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support

This activity is supported by independent educational grants from Alcon, Genentech, Regenxbio, Tarsus, Théa, and Visus.
Name Relationship Commercial Interest
Session Faculty
Eric Donnenfeld, MD (moderator) Consultant, Ownership
Consultant Allegro
Consultant Allergan
Consultant Alcon
Consultant, Ownership Aurion
Consultant Avellino Labs
Ownership Avedro
Consultant Bausch + Lomb
Consultant, Ownership CorneaGen
Consultant, Ownership Covalent
Consultant CRST
Consultant, Ownership Crystilex
Consultant BVI
Consultant Blephex
Consultant Dompe
Consultant, Ownership ELT Sight
Consultant, Ownership EyePoint Pharma
Consultant Foresight
Consultant, Ownership Glaukos
Consultant, Ownership Ivantis
Consultant Johnson & Johnson
Consultant Kala
Consultant Katena
Consultant, Ownership Lacripen
Consultant, Ownership LayerBio
Consultant, Ownership LensGen
Consultant, Ownership Mati Pharmaceuticals
Consultant, Ownership Melt Pharmaceuticals
Consultant, Ownership MDBackline
Consultant Merck
Consultant, Ownership Mimetogen
Consultant, Ownership MOA
Consultant Nanowafer
Consultant, Ownership Novabay
Consultant Novartis
Consultant Novaliq
Ownership Ocuhub
Consultant, Ownership Ocular Innovations
Consultant, Ownership Oculis
Consultant Odyssey
Consultant Omega Ophthalmics
Consultant Oyster PointTherapeutics
Consultant Pfizer
Consultant, Ownership Pogotec
Consultant Ocuhub
Consultant Omeros
Ownership Orasis
Consultant PRN
Consultant, Ownership Rayner
Consultant, Ownership ReTear
Consultant, Ownership RPS
Consultant Shire
Consultant, Ownership Strathspey Crown
Consultant SUN
Consultant, Ownership Surface
Consultant, Ownership Tarsus
Consultant, Ownership Tearlab
Consultant Tearscience
Consultant Thea
Consultant, Ownership Veracity
Consultant, Ownership Versant Ventures
Consultant, Ownership Visionary Ventures
Consultant, Ownership Visus
Consultant Zeiss
Preeya Gupta, MD (faculty) Consultant Azura
Consultant Alcon
Consultant Aldeyra
Consultant Allergan
Consultant Expert Opinion
Consultant HanAll Biopharma
Consultant J&J Vision
Consultant Kala
Consultant New World Medical
Consultant Novartis
Consultant Ocular Science
Consultant Ocular Therapeutix
Consultant Orasis
Consultant Oyster Point
Consultant Sight Sciences
Consultant Spyglass
Consultant Surface Ophthalmics
Consultant Sun Pharmaceuticals
Tear Lab
Tear Clear
Tissue Tech, Inc
Consultant Visionology
Consultant Zeiss
Leslie O'Dell, OD, FAAO (faculty) N/A Nothing to disclose
Dorothy Caputo, MA, BSN, RN, VP, Healthcare Continuing Education & Operations N/A Nothing to disclose
Michele Bielarski, RN (planner/reviewer) N/A Nothing to disclose
AKH Inc. Staff and Planners N/A Nothing to disclose
International Healthcare Media, LLC Staff and Planners N/A Nothing to disclose
All of the relevant financial relationships listed for these individuals have been mitigated.


It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content.